ArriVent BioPharma (AVBP) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on ArriVent BioPharma (AVBP) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.00 of bullish evidence against -0.26 bearish.

ArriVent BioPharma last closed at $28.46, +0.67% on the session.

Against the IVW growth benchmark the position is -0.25% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

16 graded predictions for AVBP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks ArriVent BioPharma in the 18th percentile on return on equity, where 100 is best.

ArriVent BioPharma is classified under Health Care / Biotechnology, with a market capitalisation of $1.39B.

StockMap tracks ArriVent BioPharma as the 111th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite ArriVent BioPharma ranks 216th of 344 in the group, against a group median of -0.21.